NASDAQ:ENTA Enanta Pharmaceuticals - ENTA Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Enanta Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $53.38 +2.43 (+4.77%) (As of 01/31/2023 12:00 AM ET) Add Compare Share Share Today's Range$50.39▼$53.7050-Day Range$41.13▼$53.3852-Week Range$37.59▼$79.50Volume189,682 shsAverage Volume146,389 shsMarket Capitalization$1.12 billionP/E RatioN/ADividend YieldN/APrice Target$65.88 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Enanta Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.57 Rating ScoreUpside/Downside23.4% Upside$65.88 Price TargetShort InterestHealthy4.42% of Float Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.80Based on 14 Articles This WeekInsider TradingSelling Shares$1.34 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.05) to ($0.88) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector175th out of 1,055 stocksPharmaceutical Preparations Industry81st out of 518 stocks 2.3 Analyst's Opinion Consensus RatingEnanta Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $65.88, Enanta Pharmaceuticals has a forecasted upside of 23.4% from its current price of $53.38.Amount of Analyst CoverageEnanta Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted4.42% of the float of Enanta Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverEnanta Pharmaceuticals has a short interest ratio ("days to cover") of 5.Change versus previous monthShort interest in Enanta Pharmaceuticals has recently decreased by 1.60%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldEnanta Pharmaceuticals does not currently pay a dividend.Dividend GrowthEnanta Pharmaceuticals does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEnanta Pharmaceuticals has received a 77.59% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Hepatitis medication", "Clinical research services for physical health", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Enanta Pharmaceuticals is -1.11. Previous Next 2.7 News and Social Media Coverage News SentimentEnanta Pharmaceuticals has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Enanta Pharmaceuticals this week, compared to 2 articles on an average week.Search Interest2 people have searched for ENTA on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Enanta Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Enanta Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,341,600.00 in company stock.Percentage Held by Insiders12.70% of the stock of Enanta Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions93.68% of the stock of Enanta Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Enanta Pharmaceuticals are expected to grow in the coming year, from ($4.05) to ($0.88) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Enanta Pharmaceuticals is -9.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Enanta Pharmaceuticals is -9.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEnanta Pharmaceuticals has a P/B Ratio of 3.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Enanta Pharmaceuticals (NASDAQ:ENTA) StockEnanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.Read More Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Stock News HeadlinesJanuary 31, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Host Conference Call on February 7 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal First Quarter Ended December 31, 2022January 31, 2023 | americanbankingnews.comEnanta Pharmaceuticals, Inc. Forecasted to Post Q4 2023 Earnings of ($2.10) Per Share (NASDAQ:ENTA)January 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 29, 2023 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives $66.00 Consensus PT from AnalystsJanuary 28, 2023 | americanbankingnews.comEnanta Pharmaceuticals (NASDAQ:ENTA) Price Target Cut to $49.00January 24, 2023 | nasdaq.comEnanta Pharmaceuticals (ENTA) Shares Cross Above 200 DMAJanuary 23, 2023 | americanbankingnews.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Short Interest UpdateJanuary 16, 2023 | markets.businessinsider.comSVB Securities Keeps Their Hold Rating on Enanta Pharmaceuticals (ENTA)January 31, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…January 10, 2023 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: Roche Holding AG (OtherRHHVF), Enanta Pharmaceuticals (ENTA) and Day One Biopharmaceuticals (DAWN)January 6, 2023 | finance.yahoo.comAn Intrinsic Calculation For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Suggests It's 49% UndervaluedJanuary 6, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Provide Updates on its Research and Development Programs and 2023 Outlook at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | finance.yahoo.comEnanta Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 30, 2022 | seekingalpha.comEnanta: Deep Losses In FY 2022 Look To Be Justified Given Macro LandscapeDecember 25, 2022 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Q4 2022 Earnings Call TranscriptNovember 23, 2022 | finance.yahoo.comNewsflash: Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Analysts Have Been Trimming Their Revenue ForecastsNovember 22, 2022 | finance.yahoo.comEnanta Pharmaceuticals to Participate in Two Investor Conferences in NovemberNovember 21, 2022 | seekingalpha.comEnanta Pharmaceuticals, Inc. (ENTA) Q4 2022 Earnings Call TranscriptNovember 21, 2022 | finance.yahoo.comEnanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ETNovember 18, 2022 | benzinga.comEarnings Outlook For Enanta PharmaceuticalsNovember 14, 2022 | finance.yahoo.comEnanta Pharmaceuticals to Host Conference Call on November 21 at 4:30 p.m. ET to Discuss its Financial Results for Its Fiscal Fourth Quarter and Full Year Ended September 30, 2022November 9, 2022 | finance.yahoo.comEnanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19November 3, 2022 | finance.yahoo.comInvestors in Enanta Pharmaceuticals (NASDAQ:ENTA) have unfortunately lost 51% over the last yearOctober 19, 2022 | finance.yahoo.comEnanta Pharmaceuticals Presents New Preclinical Data for EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19 at IDWeek™ 2022October 17, 2022 | finance.yahoo.comEnanta Pharmaceuticals, Inc. (ENTA)October 17, 2022 | finance.yahoo.comEnanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial VirusOctober 3, 2022 | finance.yahoo.comEnanta Pharmaceuticals Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial VirusSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ENTA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Enanta Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ENTA Company Calendar Last Earnings11/21/2022Today1/31/2023Next Earnings (Estimated)2/14/2023Fiscal Year End9/30/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ENTA CUSIPN/A CIK1177648 Webwww.enanta.com Phone(617) 607-0800Fax617-607-0530Employees155Year FoundedN/APrice Target and Rating Average Stock Price Forecast$65.88 High Stock Price Forecast$96.00 Low Stock Price Forecast$49.00 Forecasted Upside/Downside+23.4%Consensus RatingModerate Buy Rating Score (0-4)2.57 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($5.91) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-121,750,000.00 Net Margins-141.31% Pretax Margin-141.82% Return on Equity-34.73% Return on Assets-30.29% Debt Debt-to-Equity RatioN/A Current Ratio10.45 Quick Ratio10.45 Sales & Book Value Annual Sales$86.16 million Price / Sales12.94 Cash FlowN/A Price / Cash FlowN/A Book Value$15.51 per share Price / Book3.44Miscellaneous Outstanding Shares20,890,000Free Float18,233,000Market Cap$1.12 billion OptionableOptionable Beta0.48 Key ExecutivesJay R. LulyPresident, Chief Executive Officer & DirectorPaul J. MellettCFO & Senior VP-Finance & AdministrationYat Sun OrCSO, Senior Vice President-Research & DevelopmentScott T. RottinghausChief Medical Officer & Senior Vice PresidentNathaniel S. GardinerSecretary, Senior Vice President & General CounselKey Competitors23andMeNASDAQ:MEImmunoGenNASDAQ:IMGNCassava SciencesNASDAQ:SAVAAclaris TherapeuticsNASDAQ:ACRSCrinetics PharmaceuticalsNASDAQ:CRNXView All CompetitorsInsiders & InstitutionsComerica BankSold 3,360 shares on 1/26/2023Ownership: 0.051%Inspire Investing LLCBought 1,151 shares on 1/26/2023Ownership: 0.025%Allspring Global Investments Holdings LLCSold 2,065 shares on 1/23/2023Ownership: 0.017%Assenagon Asset Management S.A.Bought 29,353 shares on 1/12/2023Ownership: 0.252%Hennion & Walsh Asset Management Inc.Sold 38,995 shares on 1/12/2023Ownership: 0.151%View All Insider TransactionsView All Institutional Transactions ENTA Stock - Frequently Asked Questions Should I buy or sell Enanta Pharmaceuticals stock right now? 7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Enanta Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ENTA shares. View ENTA analyst ratings or view top-rated stocks. What is Enanta Pharmaceuticals' stock price forecast for 2023? 7 Wall Street analysts have issued 12 month target prices for Enanta Pharmaceuticals' stock. Their ENTA share price forecasts range from $49.00 to $96.00. On average, they anticipate the company's share price to reach $65.88 in the next year. This suggests a possible upside of 26.1% from the stock's current price. View analysts price targets for ENTA or view top-rated stocks among Wall Street analysts. How have ENTA shares performed in 2023? Enanta Pharmaceuticals' stock was trading at $46.52 at the start of the year. Since then, ENTA stock has increased by 12.3% and is now trading at $52.24. View the best growth stocks for 2023 here. When is Enanta Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 14th 2023. View our ENTA earnings forecast. How were Enanta Pharmaceuticals' earnings last quarter? Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) issued its quarterly earnings data on Monday, November, 21st. The biotechnology company reported ($1.27) earnings per share for the quarter, topping analysts' consensus estimates of ($1.37) by $0.10. The biotechnology company had revenue of $20.32 million for the quarter, compared to analyst estimates of $22.86 million. Enanta Pharmaceuticals had a negative net margin of 141.31% and a negative trailing twelve-month return on equity of 34.73%. The company's revenue was down 13.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.22) earnings per share. What is Jay R. Luly's approval rating as Enanta Pharmaceuticals' CEO? 5 employees have rated Enanta Pharmaceuticals Chief Executive Officer Jay R. Luly on Glassdoor.com. Jay R. Luly has an approval rating of 100% among the company's employees. This puts Jay R. Luly in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 86.0% of employees surveyed would recommend working at Enanta Pharmaceuticals to a friend. What other stocks do shareholders of Enanta Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Enanta Pharmaceuticals investors own include Cronos Group (CRON), Dollar Tree (DLTR), AbbVie (ABBV), Gilead Sciences (GILD), Intercept Pharmaceuticals (ICPT), NVIDIA (NVDA), Netflix (NFLX), GW Pharmaceuticals (GWPH), Micron Technology (MU) and Zoetis (ZTS). What is Enanta Pharmaceuticals' stock symbol? Enanta Pharmaceuticals trades on the NASDAQ under the ticker symbol "ENTA." Who are Enanta Pharmaceuticals' major shareholders? Enanta Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.25%), Hennion & Walsh Asset Management Inc. (0.15%), Yousif Capital Management LLC (0.06%), Comerica Bank (0.05%), Inspire Investing LLC (0.02%) and Allspring Global Investments Holdings LLC (0.02%). Insiders that own company stock include Bruce L A Carter, Jay R Luly, Nathalie Adda and Paul J Mellett. View institutional ownership trends. How do I buy shares of Enanta Pharmaceuticals? Shares of ENTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Enanta Pharmaceuticals' stock price today? One share of ENTA stock can currently be purchased for approximately $52.24. How much money does Enanta Pharmaceuticals make? Enanta Pharmaceuticals (NASDAQ:ENTA) has a market capitalization of $1.09 billion and generates $86.16 million in revenue each year. The biotechnology company earns $-121,750,000.00 in net income (profit) each year or ($5.91) on an earnings per share basis. How many employees does Enanta Pharmaceuticals have? The company employs 155 workers across the globe. How can I contact Enanta Pharmaceuticals? Enanta Pharmaceuticals' mailing address is 500 ARSENAL STREET, WATERTOWN MA, 02472. The official website for the company is www.enanta.com. The biotechnology company can be reached via phone at (617) 607-0800, via email at cmiceli@enanta.com, or via fax at 617-607-0530. This page (NASDAQ:ENTA) was last updated on 1/31/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.